These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15578944)

  • 1. Role of metabolism in ocular drug delivery.
    Duvvuri S; Majumdar S; Mitra AK
    Curr Drug Metab; 2004 Dec; 5(6):507-15. PubMed ID: 15578944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.
    Al-Ghananeem AM; Crooks PA
    Molecules; 2007 Mar; 12(3):373-88. PubMed ID: 17851396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular absorption behavior of palmitoyl tilisolol, an amphiphilic prodrug of tilisolol, for ocular drug delivery.
    Kawakami S; Nishida K; Mukai T; Yamamura K; Kobayashi K; Sakaeda T; Nakamura J; Nakashima M; Sasaki H
    J Pharm Sci; 2001 Dec; 90(12):2113-20. PubMed ID: 11745770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
    Babizhayev MA
    Drug Dev Ind Pharm; 2008 Oct; 34(10):1071-89. PubMed ID: 18777243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the use of prodrugs for drug delivery to the eye.
    Taskar P; Tatke A; Majumdar S
    Expert Opin Drug Deliv; 2017 Jan; 14(1):49-63. PubMed ID: 27441817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
    Fukano Y; Kawazu K
    Drug Metab Dispos; 2009 Aug; 37(8):1622-34. PubMed ID: 19477946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research of oral prodrugs: opportunities and challenges].
    Cao F; Ping QN; Chen J
    Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrugs: effective solutions for solubility, permeability and targeting challenges.
    Hu L
    IDrugs; 2004 Aug; 7(8):736-42. PubMed ID: 15334306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450-activated prodrugs: targeted drug delivery.
    Huttunen KM; Mähönen N; Raunio H; Rautio J
    Curr Med Chem; 2008; 15(23):2346-65. PubMed ID: 18855665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodrug approaches for CNS delivery.
    Rautio J; Laine K; Gynther M; Savolainen J
    AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular delivery of the beta-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analogue.
    Prokai L; Wu WM; Somogyi G; Bodor N
    J Med Chem; 1995 May; 38(11):2018-20. PubMed ID: 7783133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of xenobiotic transporters in ophthalmic drug delivery.
    Chemuturi N; Yanez JA
    J Pharm Pharm Sci; 2013; 16(5):683-707. PubMed ID: 24393552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?
    Argikar UA; Dumouchel JL; Kramlinger VM; Cirello AL; Gunduz M; Dunne CE; Sohal B
    J Pharm Sci; 2017 Sep; 106(9):2276-2281. PubMed ID: 28322939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodrugs for transdermal drug delivery - trends and challenges.
    Ita KB
    J Drug Target; 2016 Sep; 24(8):671-8. PubMed ID: 26878159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists.
    Jana S; Mandlekar S; Marathe P
    Curr Med Chem; 2010; 17(32):3874-908. PubMed ID: 20858214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What should be considered on design of a colon-specific prodrug?
    Jung Y; Kim YM
    Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.